|
|
||||||||
1 From the Eye Research Laboratories, Sight Savers of Alabama, Birmingham; and the 2 Department of Physiology and Biophysics, the University of Alabama at Birmingham.
| Abstract |
|---|
|
|
|---|
METHODS. (L)-RTR tetramer, (D)-RTR tetramer, and 5F were tested in vitro for their effects on neutrophil polarization. Synthetic 5F was also tested in vitro for its effect on the neutrophil respiratory burst. In the alkali-injured rabbit eye model, the right corneas of 48 rabbits were exposed to 1 N NaOH for 35 seconds. Sixteen animals were randomly assigned to each of three groups: phosphate-buffered saline (PBS) control; 800 µM RTR (dextrorotatory) tetramer in PBS alternating each hour with 1.5 mM RTR (levorotatory) tetramer in PBS; and 12 µM 5F in PBS. One topical drop of each substance was administered hourly (14 times per day) for 33 days. The experiment was continued until day 42 with no additional drops administered.
RESULTS. (L)-RTR tetramer and (D)-RTR tetramer inhibited neutrophil polarization activated by the PGP chemoattractants in vitro. Synthetic 5F did not inhibit neutrophil polarization in the presence of Ac-PGP or the respiratory burst of neutrophils in the presence of a metabolic stimulant derived from alkali-degraded corneas. During the entire animal experiment, statistically fewer ulcers occurred in the RTR tetramer group than in the PBS control group (43.8% vs. 87.5%, P = 0.0046). The frequency of ulceration in the 5F group (68.8%) was not significantly different from the PBS control group.
CONCLUSIONS. The reduction in the frequency of corneal ulceration by the RTR tetramer possibly resulted from its complementary binding to Ac-PGP and Me-PGP in the cornea shortly after alkali injury, leading to a reduction in the early and late infiltration of neutrophils. RTR tetramer appears to hold enough promise to warrant additional study as a therapeutic drug for the alkali-injured eye.
| Introduction |
|---|
|
|
|---|
Recognition that acetylated and methylated PGP were important mediators in this disease opened a window of therapeutic opportunity. One approach to the development of a compound inhibitory for this chemoattractant is the sense-antisense, or molecular recognition, theory.7 This concept posits that protein molecules recognize one another in a genetically defined manner. Blalock and Smith8 proposed a novel approach to molecular recognition that succeeded in predicting protein interactions with high accuracy. This method is based on the development of complementary peptides specified by ligand antisense RNA. It has been useful in designing interactive peptides, isolating receptors, and producing anti-receptor and anti-idiotypic antibodies.9 10 Using this approach, the arginine-threonine-arginine (RTR) amino acid sequence was incorporated into a tetrameric peptide designed to bind to the complementary PGP sequence. In a recent in vitro study, the RTR tetramer was shown to be a potent inhibitor of neutrophils activated by the Ac-PGP chemoattractant.11
Exclusion of neutrophils from the alkali-injured cornea is the likely key to decreasing or eliminating corneal ulceration. Inhibition of the PGP chemoattractants by the RTR tetrameric peptide in an alkali-injured eye may reduce the first neutrophilic influx. The purpose of this study was to investigate the effectiveness of this RTR tetrameric peptide in vivo. In a second experimental group, a synthetic peptide (5F) was tested, because it mimics the activity of apo A-1, which is known to inhibit the respiratory burst and degranulation of neutrophils, but not chemotaxis.12 The present study represents the first use of an antisense peptide as a therapeutic agent to treat eye disease by directly binding to, and thus inhibiting, inflammatory mediators.
| Materials and Methods |
|---|
|
|
|---|
Peptide Synthesis
The RTR tetrameric peptide
(((H2N-Arg-Thr-Arg-Gly-Gly)2-Lys)2-Lys-Ala-CONH2), containing
levorotatory (L) RTR sequences, was purchased from Lipal Biochemicals
(Gundetswil, Switzerland). The RTR tetrameric peptide
(((H2N-d-Arg-d-Thr-d-Arg-Gly-Gly)2-Lys)2-Lys-Ala-CONH2),
containing dextrorotatory (D) sequences, was synthesized manually
in the Department of Physiology and Biophysics, University of Alabama
at Birmingham, using stepwise solid-phase peptide synthesis, starting
with 3g of the Fmoc-Pal-Peg-PS resin with an initial substitution of
0.2 mmol/g resin. Dimethylformamide (DMF) was used as the solvent for
the coupling steps and the washing steps, whereas Fmoc deprotection was
achieved with 1% 1,8-diazabicyclo[5.4.0]undec-7-ene
(DBU)2% piperidine in DMF. Monitoring of the coupling and
deprotection steps was conducted using the test by Kaiser et
al.13
All amino acids were doubly coupled for 1 hour,
using as activating reagents 1-hydroxy-7-azabenzotriazole
(HOAt) for the O-pentafluorofenil ester amino acid
and
2-(1H-7-azabenzotrizol-1-yl)-1,1,3,3,tetra-methyluronium
hexaflurophosphate/diisopropylethylamine (HATU/DIPEA) for the
free acids. An excess of 5 equivalents of amino acid over the resin
substitution was used for alanine and the first lysine, 10 equivalents
for the second lysine, and 20 equivalents for the following amino
acids. The peptide was cleaved from the resins and purified.
For synthesis of Ac-PGP, the dipeptide t-Boc-PG was coupled to Pro-Merrifield resin using the dicyclohexylcarbodiimide/1-hydroxybenzotriazole procedure. After removal of the N-terminal protection and acetylation using acetic anhydride, the peptide was cleaved from the resin using anhydrous hydrofluoric acid and purified. Quantitative amino acid analysis was performed to show the correct ratio of amino acids and to determine the peptide content for calculation of the final concentration.
Me-PGP was purchased from Peninsula Laboratories (Belmont, CA). Synthetic 5F (acetyl-(AspTrpLeuLysAlaPheTyrAspLysValPheGluLysPhe-LysGluPhePhe)-NH2 ) was synthesized as previously reported.14
Purification of synthetic peptides was achieved by preparative reversed-phase high-performance liquid chromatography using a C-18 column. All synthetic peptides were identified by mass spectroscopy.
In Vitro Studies
Preparation of Mediators and Inhibitors.
Synthetic peptides were dissolved in HBSS (pH 7.3). When necessary, the
osmolality was adjusted between 280 and 320 mOsm/kg by adding a small
amount of distilled water. Zymosan was opsonized by incubating in human
serum (10 mg/ml) for 30 minutes at 37°C, centrifuged, and rinsed in
HBSS three times and resuspended in HBSS (10 mg/ml).
The respiratory burst stimulant from alkali-degraded corneas was isolated from whole bovine corneas. Corneas were excised from frozen eyes and alkali treated. The ratio of corneal dry weight to final volume of 1 N NaOH was 1:12 (wt/vol). The final volume and concentration of alkali included the water content of each cornea (456 µl), based on preliminary studies of the difference between dry (83 mg) and wet (539 mg) weights. The following method was used: 100 corneas, containing 45.6 ml water, were added to 45.6 ml 2 N NaOH and mixed. The sample was then incubated at 35°C for 24 hours. The sample was neutralized by titration with 1 N HCl to pH 7.4 and 0.05% sodium azide was added. The crude suspension was centrifuged at 15,000g for 15 minutes and the supernatant fraction collected.
The supernatant fraction was then placed in a 30,000-MWt cutoff system (Centriprep; Amicon, Beverly, MA) and centrifuged at 1500g for 30 minutes The ultraconcentrate was titrated with acetic acid to pH 5.0 and centrifuged at 15,000g for 5 minutes. The resultant pellet was extracted with 100% acetonitrile, sonicated for 30 minutes, and centrifuged at 15,000g for 5 minutes and the supernatant fraction evaporated to dryness. The residue from the acetonitrile extract was resuspended in 1 ml of a mixture of distilled water and HBSS. The osmolality was adjusted to between 270 and 310 mOsm and the pH to 7.3. A 1:50 dilution of this sample was used as the respiratory burst stimulant from alkali-degraded corneas to measure the PMN respiratory burst.
Neutrophil Isolation.
These experiments followed the tenets of the Declaration of Helsinki
and were approved by the Human Research Committee at Brookwood Medical
Center (Birmingham, AL). All donors signed written consent forms that
explained the nature and possible consequences of the study. Blood was
collected from one donor each day by venipuncture. Using the technique
of Ferrante and Thong,15
neutrophils were isolated from
fresh heparinized human blood by centrifugation with a single-density
gradient (optical density, 1.114; Hypaque, Winthrop Laboratories;
Ficoll, Sigma Chemical Co.), in accordance with a previous
paper.16
Isolated neutrophils (96%99% viability) were
resuspended in HBSS, containing 15 mM phosphate buffer, 500 µM
Ca2+, and 500 µM Mg2+, at room temperature
and gently agitated on a shaker. The purity of this cell suspension was
more than 85% neutrophils and less than 5% mononuclear cells and
platelets, with the remaining percentage consisting of red blood cells.
Purified neutrophils were used in the polarization and respiratory burst assays. All incubation mixtures were maintained between an osmolality of 280 to 320 mOsm and a pH range of 7.2 to 7.6. Cell viability for the polarization and respiratory burst assay samples was within control limits (<5% cell death) as measured by lactic dehydrogenase activity17 18 and trypan blue staining. The Students t-test was used to analyze data from the neutrophil polarization and respiratory burst experiments.
Polarization Assay.
This in vitro assay was used, before the animal experiment, to measure
the effect of inhibitors ([D]-RTR tetramer, [L]-RTR tetramer, and
5F) on neutrophil polarization activated by Ac-PGP or Me-PGP. The
polarization assay was performed in a masked fashion. The polarization
index is a measure of the frequency and degree of cellular shape change
after exposure to a chemoattractant.19
Briefly,
preincubated neutrophils (2 x 105) were mixed with
preincubated chemoattractants and/or inhibitors in a 100-µl reaction
chamber at 37°C for 5 minutes. At the end of the incubation period,
an aliquot was collected and mixed with an equal volume of 4%
glutaraldehyde for microscopic observation. Neutrophils in each sample
were observed microscopically and assigned scores of 0 (resting,
spherical cell with a smooth membrane), 1 (activated, irregular cell
with uneven membranes), or 2 (polarized, cell length more than two
times width). Scores of 100 neutrophils for each sample were added and
corrected by subtracting negative control scores (neutrophils in HBSS
only), producing a polarization index.
Respiratory Burst Assay.
The respiratory burst assay was used to test the effectiveness of the
5F inhibitor on activation of the neutrophil respiratory burst before
the alkali-injured rabbit eye experiment. This in vitro assay was
performed in a masked fashion. A luminometer (Flyte 400; Cardinal
Associates, Santa Fe, NM) was used to measure light (amplified by
luminol and calibrated in relative light units) emitted by the decay of
oxygen radicals.20
These radicals are released during the
PMN respiratory burst when triggered by opson-ized zymosan or the
respiratory burst stimulant from alkali-degraded corneas. The optimal
doses, 600 ng/ml opsonized zymosan and a 1:50 dilution of the
respiratory burst stimulant from alkali-degraded corneas, were chosen
from preliminary doseresponse studies. Briefly, 5 x
106 PMNs were suspended in HBSS, containing luminol (0.2
mg/ml) and dimethyl sulfoxide (DMSO; 0.0025%), and exposed to the 5F
inhibitor in the presence of opsonized zymosan or the respiratory burst
stimulant from alkali-degraded corneas. The samples were incubated in a
luminometer reaction chamber (total volume, 250 µl) at 35°C for 10
minutes.
In Vivo Study
Preparation of Dropping Solutions.
(L)-RTR tetramer, (D)-RTR tetramer, and 5F were dissolved in
physiologic phosphate-buffered saline (PBS) at pH 7.3 and 295310
mOsm. Constituents of the PBS solution were as follows: 137 mM NaCl,
2.7 mM KCl, 10 mM Na2 HPO4, and 1.8 mM
KH2 PO4. The concentrations of both RTR
tetramers were dictated by the limited quantities of synthetic RTR
tetramer available. The highest achievable concentration of synthetic
5F (12 µM) was dictated by its solubility in the PBS control vehicle.
Alkali Injury Model.
Animals were maintained and treated in full compliance with the ARVO
Statement on the Use of Animals in Ophthalmic and Vision Research.
Forty-eight New Zealand Dutch strain albino rabbits (Myrtles
Rabbitry, Thompson Station, TN) weighing 2.0 to 2.5 kg were
anesthetized with ketamine HCl (12 mg/kg) and xylazine (7.5 mg/kg). Two
drops of topical proparacaine (Allergan, Hormigueros, Puerto Rico) were
placed in the right eye of each rabbit. After ocular proptosis, a 12-mm
plastic well was centered on the cornea, and 0.4 ml 1 N NaOH was
instilled into the well and left for a period of 35 seconds. The alkali
was aspirated and the well irrigated with 10 ml physiological saline.
Erythromycin ointment (0.5%) was applied two times a day and study
medications administered by the technique of
Fraunfelder.21
Double-masked examinations (slit lamp and
dissecting microscopy) were conducted on Monday, Wednesday, and Friday
with photographs obtained on Wednesday. Evaluation was made for the
presence and size of epithelial defects, corneal ulceration,
perforation, and vascularization, using fluorescein where indicated.
The determination of the severity of ulceration was based on the
presence of ulceration into the anterior third, middle third, or
posterior third of the corneal stroma. When the Descemet membrane was
bared then a Descemetocele was declared. A corneal perforation was
present if fluorescein staining showed leakage of aqueous occurring
through the Descemetocele or the anterior chamber was partially or
completely collapsed.
Animals were randomly subdivided into three groups of 16 eyes each: (1)
PBS control, (2) 800 µM (D)-RTR tetramer in PBS alternating each hour
with 1.5 mM (L)-RTR tetramer in PBS, and (3) 5F (12 µM) in PBS. Each
animal received one drop of the appropriate medication 2 hours after
the alkali injury. Drops were repeated once every hour for 14 hours a
day for 33 days and then treatment was discontinued until the end of
the experiment on day 42. The frequency of ulceration between groups
was evaluated by calculating the mean ± SEM and testing for
significance using the
2 test. P <
0.05 was considered significant. The severity of ulceration
between groups was evaluated by the Mann-Whitney test. Results are
expressed as mean ± SEM, unless otherwise stated.
| Results |
|---|
|
|
|---|
(L)- or (D)-RTR Tetramer Inhibition of Neutrophil Polarization
Neutrophil polarization in the presence of 800 µM Ac-PGP
was increased 50% above the control level. (L)- and (D)-RTR tetramer
produced comparable inhibitions of this Ac-PGP induced neutrophil
polarization (Table 1)
. Neutrophil polarization in the presence of 1 mM Me-PGP was
increased 50% above the control level. Both RTR tetramers produced
similar inhibitions of this Me-PGP induced neutrophil polarization
(Table 2)
. Inhibition of Ac-PGP was two orders of magnitude greater than
inhibition of Me-PGP for both tetrameric peptides.
|
|
Effect of 5F on Neutrophil Respiratory Burst
Neutrophils exposed to opsonized zymosan produced a significantly
greater respiratory burst than control neutrophils. The synthetic 5F
peptide significantly inhibited this opsonized zymosan induced
stimulation (Fig. 1A)
. Neutrophils exposed to the respiratory burst stimulant derived from
alkali-degraded corneas produced a significantly greater respiratory
burst than control neutrophils. Synthetic 5F failed to inhibit this
respiratory burst (Fig. 1B)
. In fact, 5F significantly enhanced the
neutrophil respiratory burst triggered by this stimulant in the first 5
minutes.
|
|
|
| Discussion |
|---|
|
|
|---|
The current work concentrates on the earliest step in this complex inflammatory process. Inactivation of the PGP neutrophilic chemoattractants released in the first hours after alkali injury. The concept of applying an antisense inhibitor to the alkali-injured eye designed specifically to inactivate a neutrophil chemoattractant is an initial effort to develop a completely novel approach to this disastrous injury. This experiment demonstrates that (L)- and (D)-RTR tetramers, used alternately in the same eye, significantly reduced the incidence of corneal ulcers occurring after alkali injury. The reduction in corneal ulceration is not as great as that noted after citrate, ascorbate or metalloproteinase inhibitors, but represents the beginning of the investigative process to optimize the RTR tetramer.
Ac-PGP and Me-PGP are the primary neutrophil chemo-attractants found in the stroma as a consequence of direct hydrolysis of corneal proteins immediately after an alkali in-jury.4 5 6 34 The favorable results obtained in this animal experiment are predicated on the inhibitory effect of the RTR tetramer on the synthetic PGP chemoattractants in vitro. It is likely that the complementary binding of RTR tetramer to Ac-PGP and Me-PGP partially neutralized these chemoattractants, thereby significantly reducing the neutrophilic response in the cornea. A direct histologic evaluation of the effect of RTR tetramer on PMN infiltration, in vivo, is planned.
The delivery of higher concentrations of the RTR tetramer into the corneal stroma would probably provide even greater benefit to the alkali-injured eye. The drop solutions for the current in vivo experiment consisted of 1.5 mM (L)-RTR tetramer and 750 µM (D)-RTR tetramer, alternating every hour. These concentrations of RTR tetramer were dictated by the limited quantities of each synthetic RTR tetramer available. Analysis of a prior experiment on the penetration of citrate into the de-epithelialized rabbit cornea36 suggests that the RTR peptide solutions used in the present study may have been suboptimal. The stromal concentrations of the (L)- and (D)-RTR tetramers, resulting from topical drops, were probably lower than the previously reported in vitro concentration of (L)-RTR tetramer (30 µM) required to produce 90% inhibition of neutrophils activated by the partially purified PGP chemoattractant fraction obtained from alkali-degraded corneas.11 The optimal RTR tetramer concentration for in vivo activity is unknown.
Comparison of in vitro data on (L)- and (D)-RTR tetramers from this present study with (L)-RTR tetramer data from a previously published study11 shows similar inhibitions of neutrophils exposed to synthetic PGP chemoattractants. In the current and previous study, the (L)-RTR tetramer concentration required to produce a 90% inhibition of neutrophils in vitro was 0.5 µM and 1 µM for synthetic Ac-PGP peptide, but thirty times higher when activated by the partially purified PGP chemoattractant fraction obtained from alkali-degraded corneas (30 µM).11 We believe the reason for this disparity is that, in addition to Ac-PGP and Me-PGP, the purified alkali-degraded corneal sample contains numerous inactive peptides having a 100 to 1000 MWt. These inactive peptides may interfere, nonspecifically, with the RTR tetramer inhibition. Given that only a minute fraction of the peptides are chemoattractants in the alkali-injured cornea it would be expected that a higher concentration of the (L)-RTR tetramer (>30 µM) would be required to produce more than 90% inhibition in vivo. Doseresponse curves are planned for the RTR tetramer in vivo.
The statistically significant reduction in the frequency of ulceration in the RTR tetramer group compared with the PBS control group persisted from day 33 (P = 0.0360) to the end of the experiment (P = 0.0163), despite cessation of RTR-tetramer therapy at 33 days. Early blocking of the PGP chemoattractants may have reduced the major stimulus to further neutrophilic invasion, providing protection to the cornea. These considerations indicate that early treatment of the alkali-injured eye by RTR tetramer may be mandatory to inhibit corneal ulcer formation.
Three new ulcers formed in the RTR group after 33 days, whereas five formed in the control group. This finding combined with the earlier discussion of suboptimal concentrations of RTR tetramer suggests that the alkali-derived PGP chemoattractants, generated immediately by alkaline hydrolysis of corneal proteins, may have been incompletely neutralized by the RTR tetramers. The early PMN response begins before 12 hours and builds to a peak at approximately 2 days before further recruitment of neutrophils is noted.37 In point of fact, we do not know when the Ac-PGP and Me-PGP peptides peak and when they no longer play a part in the chemoattraction of neutrophils. These molecules may remain in the corneal stroma much longer than imagined. Nevertheless, it is logical to believe that it is important to begin treatment within 24 hours and even within several hours. This is completely feasible clinically, but the logistics for delivering the medication must be in place beforehand.
Both the (L) and (D) forms of the RTR tetramer were used in this experiment to guard against the potential enzymatic degradation of the (L)-RTR sequence in the alkali-injured cornea. The paucity of any cells in the cornea during the first couple of days after the injury augurs low enzymatic activity. In subsequent days the influx of cells may produce enzymes capable of degrading the (L)-RTR sequence. The stability of (D)-amino acid peptides in vivo and the similar biological activities of (L)- and (D)-amino acid peptides provide the rationale for administering both tetramers.38 39 40 41 Future experiments are needed to distinguish between the effectiveness of the (L)- and (D)-RTR tetramers.
Apo A-1 has been reported to inhibit receptor-activated respiratory burst and degranulation of PMNs in the presence of some inflammatory mediators, but has no effect on PMN chemoattractants.12 In the current in vitro experiments, the apo A-1 mimetic peptide, 5F (7300 MWt), had no effect on the Ac-PGP chemoattractant but produced a significant inhibition of the neutrophil respiratory burst in the presence of opson-ized zymosan. However, these same experiments demonstrate the inability of 5F to inhibit the respiratory burst of neutrophils activated with a metabolic stimulant derived from alkali-degraded corneas.42 43 In fact, this respiratory burst was significantly increased during the first 5 minutes. The in vitro failure of 5F to inhibit both mediators derived from alkali-degraded corneas and, in particular, its initial enhancing effect on the respiratory burst stimulant may explain the occurrence of more severe ulcers in the 5F-treated animals and the failure of 5F to reduce the frequency of ulcer formation.
This article represents an important step in conceptualizing, producing, and testing a drug inhibitory to chemoattractant peptides found in alkali-injured eye. Such an approach is intended to begin an iterative process in the development of more potent peptides that are able to stem the invasion of neutrophils into the cornea. Although other compounds have been found to be more potent, in most cases, there is little room for further development to enhance drug activity. In contrast, senseantisense technology offers an opportunity to manipulate the peptide compounds in a completely new class of inhibitors. The results of this article should therefore be interpreted in the context of the first phase in the development of an entirely new concept in the treatment of the alkali-injured eye.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication December 12, 2000; revised May 24, 2001; accepted June 27, 2001.
Commercial relationships policy: P.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be marked
"advertisement" in accordance with 18 U.S.C.
1734
solely to indicate this fact.
Corresponding author: Jeffrey L. Haddox, Sight Savers of Alabama, Eye Research Laboratories, 500 Robert Jemison Road, Birmingham, AL 35209. sightsavers{at}mindspring.com
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. H. van Houwelingen, N. M. Weathington, V. Verweij, J. E. Blalock, F. P. Nijkamp, and G. Folkerts Induction of lung emphysema is prevented by L-arginine-threonine-arginine FASEB J, September 1, 2008; 22(9): 3403 - 3408. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |